Conestoga Capital Advisors’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
Other funds holding IRMD
CCM
NTCM
Conestoga Capital Advisors's IRMD Position: Q2 2026 in Review
Conestoga Capital Advisors reduced its iRadimed (IRMD) stake by 0.61% in Q2 2026, selling an estimated $11.8K and leaving 21,085 shares worth $2.01M. The position accounts for 0.04% of the portfolio, ranked #73.
Conestoga Capital Advisors first reported a position in IRMD in Q4 2015 and has held it in 16 quarters since. The position peaked at $9.73M in Q3 2016. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.
- Conestoga Capital Advisors held 21,085 shares of iRadimed worth $2.01M as of Q2 2026.
- Conestoga Capital Advisors sold 130 iRadimed shares in Q2 2026, an estimated $11.8K.
- iRadimed made up 0.04% of Conestoga Capital Advisors's portfolio in Q2 2026, its #73 holding.
- Conestoga Capital Advisors first reported a position in iRadimed in Q4 2015 and has held it in 16 quarters since.
- Conestoga Capital Advisors's iRadimed position peaked at $9.73M in Q3 2016.
- 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.
Based on Conestoga Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.